CASI announced on 19 November 2020 that its partner Juventas has initiated pivotal studies of the CD19 CAR-T product CNCT19 for the treatment of B-cell non-Hodgkin lymphoma (B-NHL). The clinical study will be run by Juventas at its expense, which will be supported by its recent $65m financing round, and the two companies will subsequently co-market in China if the product is approved. Juventas has guided towards potential approval in Q422.
23 Nov 2020
CASI Pharmaceuticals - Pivotal CAR-T study initiated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CASI Pharmaceuticals - Pivotal CAR-T study initiated
CASI Pharmaceuticals, Inc. (CASI:NAS) | 0 0 0.0%
- Published:
23 Nov 2020 -
Author:
Dr Nathaniel Calloway -
Pages:
5
CASI announced on 19 November 2020 that its partner Juventas has initiated pivotal studies of the CD19 CAR-T product CNCT19 for the treatment of B-cell non-Hodgkin lymphoma (B-NHL). The clinical study will be run by Juventas at its expense, which will be supported by its recent $65m financing round, and the two companies will subsequently co-market in China if the product is approved. Juventas has guided towards potential approval in Q422.